Pharmaceuticals APAC News & Press Release Distribution

Pharmaceuticals

All
Global

Ascletis' NASH Drug ASC41(THRβ) Phase II Enrollment is Progressing as Planned

HANGZHOU and SHAOXING, China, Dec. 21, 2022 /PRNewswire/ -- The enrollment of the 52-week Phase II clinical trial of thyroid hormone receptor β (THRβ) agonist ASC41 developed in house by Gannex Pharma Co., Ltd., a wholly owned subsidiary of Ascletis Pharma Inc. (HKEX: 1672, "Ascletis"), for tr...

2022-12-21 08:00 2338

Sirnaomics Announces Interim Data from Phase I Clinical Trial of RNAi Therapeutic STP707 for Treatment of Multiple Solid Tumors

First three out of five cohorts pass safety requirements, allowing the Company to dose additional cohorts to assess safety, tolerability, pharmacokinetics and anti-tumor activity HONG KONG, GERMANTOWN, Md., and SUZHOU, China, Dec. 21, 2022 /PRNewswire/ -- Sirnaomics Ltd.(Stock Code: 2257.HK) (th...

2022-12-21 00:39 2979

AstraZenca, G42 Healthcare enter strategic partnership to manufacture pharmaceutical products in Abu Dhabi

ABU DHABI, UAE, Dec. 20, 2022 /PRNewswire/ -- Building on the ongoing efforts of the Department of Health –Abu Dhabi (DoH) in spearheading Abu Dhabi's healthcare ecosystem, AstraZeneca, a science-led biopharmaceutical and one of the top 10 biopharma companies globally, and G42 Healthcare, an AI-p...

2022-12-20 23:16 2358

AstraZenca, G42 Healthcare enter strategic partnership to manufacture pharmaceutical products in Abu Dhabi

Kira Pharmaceuticals Announces Clearance to Initiate Phase 2 Evaluation of KP104 in IgA Nephropathy (IgAN) and Complement 3 Glomerulopathy (C3G) in China and Australia

CAMBRIDGE, Mass., Dec. 20, 2022 /PRNewswire/ -- Kira Pharmaceuticals, a global biotechnology company pioneering transformational complement therapies to treat immune-mediated diseases, announced today that the Chinese National Medical Products Administration (NMPA) and the Australian Therapeutic ...

2022-12-20 20:00 2183

Carrick Therapeutics and The Menarini Group Announce Clinical Trial Collaboration to Evaluate Samuraciclib and Elacestrant Combination

Carrick to execute Phase 2 clinical trial in patients with CDK4/6i resistant HR+, HER2- metastatic breast cancer DUBLIN and FLORENCE, Italy, Dec. 19, 2022 /PRNewswire/ -- Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapie...

2022-12-19 23:07 1891

Ascletis Announces Notice of Issuance of the U.S. Patent for Oral Viral Polymerase Inhibitor ASC10 and Its Derivatives

--The issue date of the patent will be January 3, 2023 by the United States Patent and Trademark Office (USPTO). The patent number is 11,541,071 -- The issued patent covers ASC10 and its derivatives, and their uses to treat virus infections including SARS-CoV-2, monkeypox virus and respiratory s...

2022-12-19 18:10 1869

Clinical Trial Approval For The Company's Novel Adjuvanted Recombinant Shingles Vaccine REC610 In The Philippines

TAIZHOU, China, Dec. 19, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group") is pleased to announce that, the Group has recently received the clinical trial approval for its novel adjuvanted recombinant shingles vaccine, REC610, fr...

2022-12-19 13:53 2144

Prenetics Acquires ACT Genomics, Creating a Leader in Comprehensive Cancer Genetics and Precision Oncology

* Acquisition to bring germline and somatic testing, cell-free DNA-based (liquid biopsy), and tissue-genomic profiling onto a single platform * Cancer genomics testing is now standard practice for cancer care and has shown to be highly successful such as Foundation One (acquired by Roche), Gra...

2022-12-16 19:56 3090

Novavax Announces Pricing of $65 Million Public Offering of Common Stock

GAITHERSBURG, Md., Dec. 16, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the pricing of an underwritten public offering to sell 6,500,000 shares of ...

2022-12-16 14:49 4576

Novavax Announces Pricing of $150 Million Offering of Convertible Senior Notes

GAITHERSBURG, Md., Dec. 16, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the pricing of an offering of$150 million aggregate principal amount of its ...

2022-12-16 14:18 3601

Bioved Pharmaceuticals, Inc. announces the results of its Phase III Randomized Clinical Trial in Moderate Covid-19 with Artovid-20®, a natural plant-based oral product

SAN JOSE, Calif., Dec. 16, 2022 /PRNewswire/ -- Published Nov 25, 2022 in the highly respected peer-reviewed journal Phytotherapy Research, results show statistically significant reduction in duration of illness and severity scores of the symptoms associated with Covid-19. In addition, statistica...

2022-12-16 01:30 1949

Nevisense for skin barrier evaluation included in large Australian birth cohort study

STOCKHOLM, Dec. 15, 2022 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders announced today that SciBase has received an order for skin barrier assessment products to be included in one of the world's large...

2022-12-15 15:50 1493

Pharming announces positive interim analysis data from open-label extension study of leniolisib in presentation at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition

V. Koneti Rao, MD, shared new evidence of long-term safety and hematologic response in patients who received leniolisib to treat APDS, a rare primary immunodeficiency Interim analysis demonstrated leniolisib to be well tolerated and indicated the durability of the efficacy results seen in the Ph...

2022-12-15 14:00 2360

IND Application of Biosyngen's Cell Therapy (BRG01) for Nasopharyngeal Cancer Approved by China NMPA

GUANGZHOU, China , Dec. 15, 2022 /PRNewswire/ -- On Dec. 14th, 2022, Guangzhou Biosyngen Co., Ltd. (hereinafter as "Biosyngen") made an announcement on the approval granted by the Center for Drug Evaluation (CDE) ofChina's National Medical Products Administration (NMPA) for the company's IND appl...

2022-12-15 13:08 3700

IND Application of Biosyngen's Cell Therapy (BRG01) for Nasopharyngeal Cancer Approved by China NMPA

"Gowajee" - a Thai Speech-Recognition AI from Chula

BANGKOK, Dec. 15, 2022 /PRNewswire/ -- Chula Engineering professors have designed "Gowajee", a Thai-language speech recognition AI with the accuracy of a native speaker that keeps users' data secure – now rolled out in call centers, and being used for depression patients screening.

2022-12-15 09:00 2786

Innovent and LG Chem Announce Strategic Collaboration for Tigulixostat, a Novel Non-Purine Xanthine Oxidase Inhibitor for the Treatment of Gout Disease

ROCKVILLE, Md. and SUZHOU, China, Dec. 15, 2022 /PRNewswire/ -- Innovent Biologics ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune, ophthalmology and other m...

2022-12-15 08:00 3131

Alternative Bio Launches with USD 15M Series Seed Financing Led by Eight Roads Ventures with F-Prime Capital and Sequoia China Seed Fund

SINGAPORE, Dec. 15, 2022 /PRNewswire/ -- Alternative Bio Inc. ("ABio"), a privately held biotechnology company developing novel therapeutics targeting a previously untapped class of post-translational modifying enzymes announced today its $15 million Series Seed financing co-led by Eight Roads Ve...

2022-12-15 08:00 2595

Everest Medicines Announces New mRNA Rabies Vaccine Program and Achievement of Preclinical Proof-of-Concept Milestone

Rabies program, as the first non-COVID19 vaccine developed with a specialized mRNA platform, highlights Everest's discovery capabilities Clinically validated mRNA platform is shown to generate differentiated products across a range of indications SHANGHAI, Dec. 15, 2022 /PRNewswire/ -- Everest M...

2022-12-15 08:00 5903

Sirnaomics Announces Positive Interim Data from Phase IIb Clinical Trial of STP705 in Adults with Cutaneous Squamous Cell Carcinoma In Situ

Dose escalation cohort study is evaluating the safety, tolerability and efficacy of various doses of STP705 administered as intralesional injection in subjects with isSCC GERMANTOWN, Md. and SUZHOU BIOBAY, China, Dec. 14, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock...

2022-12-14 23:47 2182

Superior Results Of The Comparative Study Of The Company's Recombinant Two-Component COVID-19 Vaccine ReCOV As Compared To International Mainstream mRNA Vaccine

TAIZHOU, China, Dec. 14, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group") is pleased to announce that positive results were achieved for its sequential booster vaccination Phase II study of the recombinant twocomponent COVID-19 ...

2022-12-14 15:17 3919

1 ... 49 50 515253 54 55 ... 181